MIRA Pharmaceuticals Inc./$MIRA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
- Ticker
- $MIRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Miami, United States
- Website
- mirapharmaceuticals.com
MIRA Metrics
BasicAdvanced
$26M
-
-$0.86
1.55
-
Price and volume
Market cap
$26M
Beta
1.55
52-week high
$1.69
52-week low
$0.51
Average daily volume
152K
Financial strength
Current ratio
200.076
Quick ratio
198.746
Profitability
Management effectiveness
Return on assets (TTM)
-129.55%
Return on equity (TTM)
-217.12%
Valuation
Price to book
3.2
Price to tangible book (TTM)
3.2
Price to free cash flow (TTM)
-4.829
Free cash flow yield (TTM)
-20.71%
Free cash flow per share (TTM)
-0.129
Growth
Earnings per share change (TTM)
85.76%
3-year earnings per share growth (CAGR)
38.27%
MIRA Financial Performance
Revenues and expenses
MIRA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.